Department of Gastroenterology, Sismanogleion General Hospital, Athens, Greece.
Dig Dis Sci. 2011 Dec;56(12):3590-5. doi: 10.1007/s10620-011-1761-4. Epub 2011 Jun 2.
Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is elevated in the gastric juice and in cultures of gastric mucosa of patients with peptic ulcer disease (PUD). Its application as a surrogate marker for the treatment of PUD was assessed.
From 138 eligible patients, 96 were enrolled; 50 with duodenal ulcer, 29 with gastric ulcer and 17 with chronic gastritis. Patients were endoscoped twice; once before treatment and once after treatment. Biopsy specimens were collected for histopathologic estimation of gastritis. Blood was sampled prior to each endoscopy. Serum was collected and sTREM-1 was measured by an enzyme immunoabsorbent assay ( http://www.clinicaltrials.gov identifier NCT00534443).
At the end of treatment sTREM-1 was either: (a) below the limit of detection (this occurred in 62 patients and it was accompanied by lacks signs of residual disease in 58 patients, 93.5%); or (b) above the limit of detection (this occurred in 17 patients and it was accompanied by residual disease in 14 patients, 82.3%) (p < 0.0001). Odds ratio for complete healing of peptic ulcer with sTREM-1 below detection limit was 5.30 (95% CI: 1.89-14.83, p < 0.001) compared to serum sTREM-1 above the limit of detection.
Serum sTREM-1 below detection limit may effectively distinguish patients who successfully completed therapy for PUD from those with residual disease and apply as a surrogate marker.
可溶性髓系细胞触发受体-1（sTREM-1）在消化性溃疡病（PUD）患者的胃液和胃黏膜培养物中升高。评估其作为 PUD 治疗替代标志物的应用。
从 138 名合格患者中，纳入 96 名患者；其中十二指肠溃疡 50 例，胃溃疡 29 例，慢性胃炎 17 例。患者接受了两次内镜检查；一次在治疗前，一次在治疗后。采集活检标本进行胃炎的组织病理学评估。每次内镜检查前均采集血样。通过酶免疫吸附测定法（http://www.clinicaltrials.gov 标识符 NCT00534443）测量血清中的 sTREM-1。
在治疗结束时，sTREM-1 要么：（a）低于检测限（这种情况发生在 62 名患者中，其中 58 名患者无残留疾病迹象，占 93.5%）；要么（b）高于检测限（这种情况发生在 17 名患者中，其中 14 名患者有残留疾病，占 82.3%）（p<0.0001）。与血清 sTREM-1 高于检测限相比，sTREM-1 低于检测限的消化性溃疡完全愈合的优势比为 5.30（95%CI：1.89-14.83，p<0.001）。
血清 sTREM-1 低于检测限可能有效区分成功完成 PUD 治疗的患者和有残留疾病的患者，并作为替代标志物应用。
